Report Detail
Global Acalabrutinib Maleate Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4706261 |
- 09 June, 2026 |
- Global |
- 70 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Acalabrutinib Maleate market size was valued at US$ 3620 million in 2025 and is forecast to a readjusted size of US$ 10679 million by 2032 with a CAGR of 17.9% during review period.
Acalabrutinib Maleate is the maleate salt form of acalabrutinib, a highly selective and irreversible Bruton’s tyrosine kinase (BTK) inhibitor. As a novel targeted antineoplastic agent, it exerts antitumor effects by specifically binding to BTK and blocking downstream signaling pathways, thereby effectively inhibiting the proliferation, activation, and survival of B-cells. Optimized in structure, it demonstrates higher target selectivity and a more favorable safety profile compared with earlier BTK inhibitors, and is clinically indicated for the treatment of various B-cell malignancies. The maleate salt form significantly improves the water solubility, stability, and bioavailability of acalabrutinib, making it suitable for oral administration and large-scale pharmaceutical development. With a well-defined mechanism of action, reliable clinical efficacy, and good tolerability, Acalabrutinib Maleate has become an important option in clinical practice and a key product in the global market for hematologic oncology drugs.In 2025, global Acalabrutinib Maleate production reached approximately 58.6 million bottles.
Acalabrutinib Maleate, marketed as Calquence by AstraZeneca, operates in a highly competitive global BTK inhibitor market, where it has established a strong commercial presence as a leading second-generation targeted therapy for B-cell malignancies. Positioned as a more selective and better-tolerated alternative to first-generation treatments, it has gained rapid adoption across major markets, driven by robust clinical data supporting superior safety profiles and favorable efficacy in chronic lymphocytic leukemia and mantle cell lymphoma. The market landscape is defined by intense rivalry with other second-generation agents and evolving competition from emerging third-generation non-covalent BTK inhibitors and fixed-duration combination regimens, prompting continuous expansion of clinical indications and strategic development of companion diagnostics. Geographic growth remains robust in North America and Europe, with accelerating penetration in Asia-Pacific markets fueled by regulatory approvals, favorable reimbursement policies, and increasing adoption of precision oncology. Despite pricing pressures and generic threats to older therapies, Acalabrutinib Maleate sustains strong market momentum through differentiated clinical positioning, ongoing pipeline innovation, and expanded use in combination therapies, solidifying its role as a cornerstone agent in modern hematologic cancer care.
This report is a detailed and comprehensive analysis for global Acalabrutinib Maleate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Acalabrutinib Maleate market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Acalabrutinib Maleate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Acalabrutinib Maleate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Acalabrutinib Maleate market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Acalabrutinib Maleate
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Acalabrutinib Maleate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Acalabrutinib Maleate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
100 mg / tablet
100 mg / capsule
Market segment by Dosage Form
Tablet
Capsule
Market segment by Combination Therapy
In Combination With Anti-CD20 Monoclonal Antibodies (e.g., Obinutuzumab
In Combination With BCL-2 Inhibitors
Market segment by Sales Channel
Hospital
Retail
Online
Market segment by Application
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Mantle Cell Lymphoma (MCL)
Others
Major players covered
AstraZeneca
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Acalabrutinib Maleate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Acalabrutinib Maleate, with price, sales quantity, revenue, and global market share of Acalabrutinib Maleate from 2021 to 2026.
Chapter 3, the Acalabrutinib Maleate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Acalabrutinib Maleate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Acalabrutinib Maleate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Acalabrutinib Maleate.
Chapter 14 and 15, to describe Acalabrutinib Maleate sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Acalabrutinib Maleate Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 100 mg / tablet
- 1.3.3 100 mg / capsule
- 1.4 Market Analysis by Dosage Form
- 1.4.1 Overview: Global Acalabrutinib Maleate Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
- 1.4.2 Tablet
- 1.4.3 Capsule
- 1.5 Market Analysis by Combination Therapy
- 1.5.1 Overview: Global Acalabrutinib Maleate Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
- 1.5.2 In Combination With Anti-CD20 Monoclonal Antibodies (e.g., Obinutuzumab
- 1.5.3 In Combination With BCL-2 Inhibitors
- 1.6 Market Analysis by Sales Channel
- 1.6.1 Overview: Global Acalabrutinib Maleate Consumption Value by Sales Channel: 2021 Versus 2025 Versus 2032
- 1.6.2 Hospital
- 1.6.3 Retail
- 1.6.4 Online
- 1.7 Market Analysis by Application
- 1.7.1 Overview: Global Acalabrutinib Maleate Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.7.2 Chronic Lymphocytic Leukemia (CLL)
- 1.7.3 Small Lymphocytic Lymphoma (SLL)
- 1.7.4 Mantle Cell Lymphoma (MCL)
- 1.7.5 Others
- 1.8 Global Acalabrutinib Maleate Market Size & Forecast
- 1.8.1 Global Acalabrutinib Maleate Consumption Value (2021 & 2025 & 2032)
- 1.8.2 Global Acalabrutinib Maleate Sales Quantity (2021-2032)
- 1.8.3 Global Acalabrutinib Maleate Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 AstraZeneca
- 2.1.1 AstraZeneca Details
- 2.1.2 AstraZeneca Major Business
- 2.1.3 AstraZeneca Acalabrutinib Maleate Product and Services
- 2.1.4 AstraZeneca Acalabrutinib Maleate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 AstraZeneca Recent Developments/Updates
3 Competitive Environment: Acalabrutinib Maleate by Manufacturer
- 3.1 Global Acalabrutinib Maleate Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Acalabrutinib Maleate Revenue by Manufacturer (2021-2026)
- 3.3 Global Acalabrutinib Maleate Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Acalabrutinib Maleate by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Acalabrutinib Maleate Manufacturer Market Share in 2025
- 3.4.3 Top 6 Acalabrutinib Maleate Manufacturer Market Share in 2025
- 3.5 Acalabrutinib Maleate Market: Overall Company Footprint Analysis
- 3.5.1 Acalabrutinib Maleate Market: Region Footprint
- 3.5.2 Acalabrutinib Maleate Market: Company Product Type Footprint
- 3.5.3 Acalabrutinib Maleate Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Acalabrutinib Maleate Market Size by Region
- 4.1.1 Global Acalabrutinib Maleate Sales Quantity by Region (2021-2032)
- 4.1.2 Global Acalabrutinib Maleate Consumption Value by Region (2021-2032)
- 4.1.3 Global Acalabrutinib Maleate Average Price by Region (2021-2032)
- 4.2 North America Acalabrutinib Maleate Consumption Value (2021-2032)
- 4.3 Europe Acalabrutinib Maleate Consumption Value (2021-2032)
- 4.4 Asia-Pacific Acalabrutinib Maleate Consumption Value (2021-2032)
- 4.5 South America Acalabrutinib Maleate Consumption Value (2021-2032)
- 4.6 Middle East & Africa Acalabrutinib Maleate Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Acalabrutinib Maleate Sales Quantity by Type (2021-2032)
- 5.2 Global Acalabrutinib Maleate Consumption Value by Type (2021-2032)
- 5.3 Global Acalabrutinib Maleate Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Acalabrutinib Maleate Sales Quantity by Application (2021-2032)
- 6.2 Global Acalabrutinib Maleate Consumption Value by Application (2021-2032)
- 6.3 Global Acalabrutinib Maleate Average Price by Application (2021-2032)
7 North America
- 7.1 North America Acalabrutinib Maleate Sales Quantity by Type (2021-2032)
- 7.2 North America Acalabrutinib Maleate Sales Quantity by Application (2021-2032)
- 7.3 North America Acalabrutinib Maleate Market Size by Country
- 7.3.1 North America Acalabrutinib Maleate Sales Quantity by Country (2021-2032)
- 7.3.2 North America Acalabrutinib Maleate Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Acalabrutinib Maleate Sales Quantity by Type (2021-2032)
- 8.2 Europe Acalabrutinib Maleate Sales Quantity by Application (2021-2032)
- 8.3 Europe Acalabrutinib Maleate Market Size by Country
- 8.3.1 Europe Acalabrutinib Maleate Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Acalabrutinib Maleate Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Acalabrutinib Maleate Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Acalabrutinib Maleate Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Acalabrutinib Maleate Market Size by Region
- 9.3.1 Asia-Pacific Acalabrutinib Maleate Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Acalabrutinib Maleate Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Acalabrutinib Maleate Sales Quantity by Type (2021-2032)
- 10.2 South America Acalabrutinib Maleate Sales Quantity by Application (2021-2032)
- 10.3 South America Acalabrutinib Maleate Market Size by Country
- 10.3.1 South America Acalabrutinib Maleate Sales Quantity by Country (2021-2032)
- 10.3.2 South America Acalabrutinib Maleate Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Acalabrutinib Maleate Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Acalabrutinib Maleate Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Acalabrutinib Maleate Market Size by Country
- 11.3.1 Middle East & Africa Acalabrutinib Maleate Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Acalabrutinib Maleate Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Acalabrutinib Maleate Market Drivers
- 12.2 Acalabrutinib Maleate Market Restraints
- 12.3 Acalabrutinib Maleate Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Acalabrutinib Maleate and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Acalabrutinib Maleate
- 13.3 Acalabrutinib Maleate Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Acalabrutinib Maleate Typical Distributors
- 14.3 Acalabrutinib Maleate Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Acalabrutinib Maleate. Industry analysis & Market Report on Acalabrutinib Maleate is a syndicated market report, published as Global Acalabrutinib Maleate Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Acalabrutinib Maleate market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
